- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06281847
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia (RESOLVE AML001)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Besançon Cedex, France
- Besançon Regional and University Hospital
-
Contact:
- Eric Deconinck
-
Principal Investigator:
- Eric Deconinck
-
Paris, France
- Hospital Saint Louis
-
Principal Investigator:
- Nicolas Boissel
-
Contact:
- Nicolas Boissel
-
-
-
-
-
Munich, Germany
- Ludwig-Maximilians University of Munich
-
Contact:
- Marion Subklewe
-
Principal Investigator:
- Marion Subklewe
-
Ulm, Germany
- University Hospital Ulm
-
Contact:
- Elisa Sala
-
Principal Investigator:
- Elisa Sala
-
-
-
-
-
Barcelona, Spain
- Vall d'Hebron University Hospital
-
Principal Investigator:
- Pere Barba
-
Contact:
- Pere Barba
-
-
-
-
-
Stockholm, Sweden
- Karolinska University Hospital
-
Contact:
- Stephan Mielke
-
Principal Investigator:
- Stephan Mielke
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with active (> 5 % blasts in bone marrow) r/r AML (WHO 2022) who have exhausted their therapeutic alternatives or have contraindications to these alternatives as judged by the treating physician defined as either:
a. Primary refractory: i. Patients who failed after two cycles of intensive induction including high-dose and/or standard dose cytarabine (including liposomal formulation), +/- anthracycline, +/- antimetabolite, +/- targeted therapy or ii. Older patients or patients unfit to receive intensive induction courses who failed after two cycles of venetoclax + azacitidine or 4 cycles of azacitidine b. Relapsing: i. Patients with early relapse after CR to first line therapy (within ≤ 6 months after CR1) or ii. Patients with relapse after later lines of therapy (Relapse after CR≥2) c. Patients relapsing after allogeneic hematopoietic stem cell transplant: i. Patients must be at least 3 months from hematopoietic stem cell transplant (HSCT) at the time of consent, and ii. Off immunosuppression for at least 1 month at the time of consent, and iii. Have no active graft versus host disease (GvHD)
- Have a circulating blast count of less than 20,000/mm3 (control with hydroxyurea is allowed)
- Absolute Lymphocyte count of >200/mm3
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Life expectancy of more than 3 months
- Patient is ≥ 18 years of age at the time of informed consent
- Read, understood, and signed the informed consent form (ICF) prior to any study procedures
- Patient is willing and able to adhere to the study visit schedule and other protocol requirements
- Eligible for leukapheresis
- Treatment-related toxicities of previous therapies have completely resolved
Adequate organ function as confirmed by clinical laboratory values, defined as:
- Adequate bone marrow function to receive LDC as assessed by the Investigator
- Serum creatinine [< 1.5 x the upper limit of normal (ULN) or creatinine clearance (CrCl) > 45 mL/min] (estimated by Cockcroft Gault or Modification of Diet in Renal Disease (MDRD); see Appendix 14.3 for calculation)
- Alanine aminotransferase [≤ 3 x ULN and total bilirubin < 1.5 mg/dL (or < 3.0 mg/dL] for patients with Gilbert's syndrome or leukemic infiltration of the liver)]
- Adequate pulmonary function, defined as [≤ Grade 1 dyspnoea according to CTCAE and oxygen saturation (SaO2) ≥ 92% on room air and forced expiratory volume in the first second ≥ 50%]
- Ejection fraction > 40% assessed by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 1 month before CCTx-001 infusion
- Women of childbearing potential* (WOCBP) must have a negative serum pregnancy test performed at screening and within 7 days before enrolment
- WOCBP or males whose sexual partners are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 12 months after the last dose of LDC. For the definition and list of highly effective methods of contraception.
Exclusion Criteria:
- Patients with an acute promyelocytic leukaemia: t(15;17)(q22;q12); (promyelocytic leukaemia/retinoic acid receptor alpha) and variants
- Patients with active central nervous system (CNS) leukaemia involvement. If the patient has prior history of CNS leukaemia, they must have a negative cerebrospinal fluid (CSF) assessment and magnetic resonance imaging (MRI) or computed tomography (if MRI is not feasible) of the brain demonstrating no evidence of CNS disease
- Patients with isolated extramedullary AML disease
- Patients who received previous treatment targeting IL-1RAP or previous gene therapy
- Patients who underwent allo-HSCT within 90 days prior to leukapheresis
- Patients who received donor lymphocyte infusion within 60 days prior to leukapheresis
- Patients with active GvHD
Patients with history of another primary malignancy other than disease under study unless the patient has been free of the disease for ≥ 2 years, except for the following non-invasive malignancies:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histologic finding of prostate cancer (T1a or T1b) or prostate cancer that is curative
- Other completely resected stage 1 solid tumour with low risk for recurrence
- Presence of systemic fungal, bacterial, viral, or other infection (including tuberculosis) that is uncontrolled despite appropriate antibiotics or other treatments
- Active or prior history of hepatitis B or hepatitis C infection
- History of or active human immunodeficiency virus (HIV) infection
- Active macrophage activation syndrome (MAS) as evidenced by laboratory abnormalities (e.g.: elevated ferritin, elevated triglycerides, haemophagocytosis on the bone marrow sample) and/or clinical signs
- History or presence of an active and clinically relevant CNS disorder such as epilepsy, generalised seizure disorder, paresis, aphasia, stroke, cerebral oedema, severe brain injury, dementia, multiple sclerosis, Parkinson's disease, cerebellar disease, organic brain syndrome, or posterior reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement
- Patients with active autoimmune disorders or active neurological or inflammatory disorders (e.g., Guillain-Barre Syndrome, Amyotrophic Lateral Sclerosis) requiring immunosuppressive therapy or corticosteroid therapy (defined as >20 mg/day prednisone or equivalent). Physiologic replacement, topical, and inhaled steroids are permitted.
Use of the following (see Section 8.3 for full details):
- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis or 72 hours prior to CCTx-001 infusion. Physiologic replacement, topical, and inhaled steroids are permitted.
- Immunosuppressive therapies within 4 weeks prior to signing the ICF (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-tumour necrosis factor [TNF], anti-IL-6, or anti-IL-6 receptor [IL-6R])
- Cytotoxic chemotherapeutic agents (including intrathecal) within 14 days prior to leukapheresis.
- Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
- Experimental agents within 4 weeks prior to signing the ICF unless no response or progressive disease (PD) is documented on the experimental therapy and at least 3 half-lives have elapsed prior to signing the ICF.
- Therapeutic anticoagulation
History of any one of the following cardiovascular conditions within the past 6 months prior to signing the ICF:
- Class III or IV heart failure as defined by the New York Heart Association
- Cardiac angioplasty or stenting
- Myocardial infarction
- Unstable angina
- Other clinically significant cardiac disease
- Known hypersensitivity to DMSO or other excipients
- Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or unwillingness or inability to follow the procedures required in the protocol.
- Abnormal findings and/or clinically significant Grade ≥3 non-haematological toxicity and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety.
- Presence of any condition that confounds the ability to interpret data from the study based on Investigator´s judgement.
- Any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
- Pregnant or nursing women. NOTE: WOCBP must have a negative serum pregnancy test performed within 48 hours of starting LDC
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open Label CCTx-001 infusion
CCTx-001 infusion 2 to 7 days after completion of LDC
|
Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: To evaluate the safety, tolerability, and to define the recommended phase 2 dose (RP2D) of CCTx-001
Time Frame: Up to 28 days
|
Frequency, severity, relationship and persistence of adverse events (AEs) and dose-limiting toxicity (DLTs)
|
Up to 28 days
|
Phase 2: To evaluate the clinical activity, as assessed by the composite complete response rate, in patients treated with CCTx-001
Time Frame: Up to 3 months
|
Composite complete response rate (cCRR) defined as the proportion of patients with best overall response, as assessed by Independent Review Committee (IRC) based on European LeukemiaNet (ELN) 2022 criteria, at complete remission (CR), CR with partial haematologic recovery (CRh), or CR with incomplete haematologic recovery (CRi).
|
Up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2: To evaluate the clinical activity, as assessed by the complete remission rate, in patients treated with CCTx-001
Time Frame: Up to 3 months
|
Complete remission rate (CRR) defined as the proportion of patients with best overall response, as assessed by IRC based on ELN 2022 criteria, at CR.
|
Up to 3 months
|
Phase 1: To evaluate the clinical activity, as assessed by the composite complete response rate, in patients treated with CCTx-001
Time Frame: Up to 3 months
|
cCRR
|
Up to 3 months
|
Phase 2: To assess the safety of CCTx-001
Time Frame: Up to 15 years
|
Frequency, severity, relationship and persistence of AEs
|
Up to 15 years
|
Phase 2: To assess HRQoL for patients treated with CCTx-001
Time Frame: Up to 6 months
|
Changes in Health-related quality of life (HRQoL) using global health/QoL, fatigue, physical and cognitive functioning subscales of the EORTC quality of life questionnaire-C30 (QLQ-C30)
|
Up to 6 months
|
Phase 2: To assess HRQoL for patients treated with CCTx-001
Time Frame: Up to 24 months
|
Changes in Health-related quality of life (HRQoL) using the Hematological Malignancy specific Patient Reported Outcome Measures (HM-PRO) tools
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 3 months
|
Objective response rate (ORR)
|
Up to 3 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
event-free survival (EFS)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
relapse-free survival (RFS)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 15 years
|
overall survival (OS)
|
Up to 15 years
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
duration of response (DOR)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
cumulative incidence of relapse (CIR)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
cumulative incidence of death (CID)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 24 months
|
time to composite complete response (TTcCR)
|
Up to 24 months
|
Phase 1 & 2: To assess additional parameters of clinical activity in patients treated with CCTx-001
Time Frame: Up to 3 months
|
time to response (TTR) according to ELN 2022 criteria and minimal residual disease (MRD) responses
|
Up to 3 months
|
Phase 1 & 2: To evaluate the overall safety and the tolerability of CCTx-001
Time Frame: Up to 15 years
|
Frequency and severity of AEs and laboratory abnormalities
|
Up to 15 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCTx-001-AML-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia, in Relapse
-
University of FreiburgCompletedAcute Myeloid Leukemia, in RelapseGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
UNC Lineberger Comprehensive Cancer CenterMerck Sharp & Dohme LLCActive, not recruitingAcute Myeloid Leukemia, in RelapseUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
St. Jude Children's Research HospitalAbbVie; Gateway for Cancer Research; Karyopharm Therapeutics IncRecruitingRefractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous LineageUnited States
-
All India Institute of Medical Sciences, New DelhiUnknown
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Keystone Nano, IncMilton S. Hershey Medical Center; University of VirginiaNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, RefractoryUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on CCTx-001
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Astrogen, Inc.RecruitingAutism Spectrum DisorderKorea, Republic of
-
StimuSILAnkara City Hospital Bilkent; Istanbul University - Cerrahpasa (IUC)RecruitingAndrogenetic Alopecia | Hair Loss | Male Pattern Baldness | Hair Loss/Baldness | Pattern BaldnessTurkey
-
MediciNovaCompletedInterstitial CystitisUnited States